The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) closed the day trading at $21.49 up 0.42% from the previous closing price of $21.4. In other words, the price has increased by $0.42 from its previous closing price. On the day, 0.53 million shares were traded. AVDL stock price reached its highest trading level at $21.57 during the session, while it also had its lowest trading level at $21.4.
Ratios:
For a better understanding of AVDL, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 22.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 57.05. For the most recent quarter (mrq), Quick Ratio is recorded 2.37 and its Current Ratio is at 2.76. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.37.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 21 ’25 when Palczuk Linda bought 5,000 shares for $7.93 per share. The transaction valued at 39,640 led to the insider holds 67,900 shares of the business.
Thornton Peter J. bought 10,000 shares of AVDL for $80,450 on Jan 13 ’25. The Director now owns 104,055 shares after completing the transaction at $8.04 per share. On Jan 13 ’25, another insider, Ende Eric J, who serves as the Director of the company, bought 30,000 shares for $7.84 each. As a result, the insider paid 235,218 and bolstered with 208,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVDL now has a Market Capitalization of 2105828480 and an Enterprise Value of 2044442752. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.44 while its Price-to-Book (P/B) ratio in mrq is 21.27. Its current Enterprise Value per Revenue stands at 8.227 whereas that against EBITDA is 757.482.
Stock Price History:
The Beta on a monthly basis for AVDL is 1.26, which has changed by 0.8541846 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, AVDL has reached a high of $23.57, while it has fallen to a 52-week low of $6.38. The 50-Day Moving Average of the stock is 19.97%, while the 200-Day Moving Average is calculated to be 78.26%.
Shares Statistics:
Over the past 3-months, AVDL traded about 2.83M shares per day on average, while over the past 10 days, AVDL traded about 3671410 shares per day. A total of 97.23M shares are outstanding, with a floating share count of 93.44M. Insiders hold about 4.48% of the company’s shares, while institutions hold 84.94% stake in the company. Shares short for AVDL as of 1763078400 were 6654943 with a Short Ratio of 2.35, compared to 1760486400 on 9982108. Therefore, it implies a Short% of Shares Outstanding of 6654943 and a Short% of Float of 7.95.
Earnings Estimates
The stock of Avadel Pharmaceuticals plc (AVDL) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.13, with high estimates of $0.17 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.79 and $0.11 for the fiscal current year, implying an average EPS of $0.28. EPS for the following year is $0.78, with 8.0 analysts recommending between $1.14 and $0.58.
Revenue Estimates
5 analysts predict $80.3M in revenue for . The current quarter. It ranges from a high estimate of $83M to a low estimate of $79.3M. As of . The current estimate, Avadel Pharmaceuticals plc’s year-ago sales were $50.41MFor the next quarter, 5 analysts are estimating revenue of $80.07M. There is a high estimate of $87M for the next quarter, whereas the lowest estimate is $75M.
A total of 5 analysts have provided revenue estimates for AVDL’s current fiscal year. The highest revenue estimate was $281.1M, while the lowest revenue estimate was $274.9M, resulting in an average revenue estimate of $277.73M. In the same quarter a year ago, actual revenue was $169.12MBased on 10 analysts’ estimates, the company’s revenue will be $359.06M in the next fiscal year. The high estimate is $378.3M and the low estimate is $345.1M.